OTCMKTS:CAPS - Capstone Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.0260 0.00 (0.00 %)
(As of 05/22/2019 01:33 PM ET)
Previous Close$0.03
Today's Range$0.0260 - $0.0260
52-Week Range$0.0120 - $0.06
Volume22,382 shs
Average Volume9,115 shs
Market Capitalization$1.41 million
P/E RatioN/A
Dividend YieldN/A
Capstone Therapeutics Corp., a biotechnology company, develops and sells novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

Receive CAPS News and Ratings via Email

Sign-up to receive the latest news and ratings for CAPS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolOTCMKTS:CAPS



Sales & Book Value

Annual Sales$2 million
Book Value($0.04) per share


Net Income$-380,000.00


Market Cap$1.41 million
Next Earnings Date8/12/2019 (Estimated)
OptionableNot Optionable

Capstone Therapeutics (OTCMKTS:CAPS) Frequently Asked Questions

What is Capstone Therapeutics' stock symbol?

Capstone Therapeutics trades on the OTCMKTS under the ticker symbol "CAPS."

How were Capstone Therapeutics' earnings last quarter?

Capstone Therapeutics Corp (OTCMKTS:CAPS) posted its quarterly earnings results on Monday, August, 13th. The biotechnology company reported $0.02 earnings per share for the quarter. The biotechnology company earned $2 million during the quarter. View Capstone Therapeutics' Earnings History.

When is Capstone Therapeutics' next earnings date?

Capstone Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August 12th 2019. View Earnings Estimates for Capstone Therapeutics.

Has Capstone Therapeutics been receiving favorable news coverage?

Press coverage about CAPS stock has trended neutral recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Capstone Therapeutics earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future.

Who are some of Capstone Therapeutics' key competitors?

What other stocks do shareholders of Capstone Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Capstone Therapeutics investors own include Energy Transfer LP Unit (ET), Energy Transfer Equity LP Unit (ETE), Extreme Networks (EXTR), Endocyte (ECYT), Determine (DTRM), Cisco Systems (CSCO), Ceragon Networks (CRNT), BioLife Solutions (BLFS), Ballard Power Systems (BLDP) and Booking (BKNG).

Who are Capstone Therapeutics' key executives?

Capstone Therapeutics' management team includes the folowing people:
  • Mr. John M. Holliman III, Exec. Chairman & Principal Exec. Officer (Age 65)
  • Mr. Leslie M. Taeger, Sr. VP, CFO and Principal Accounting & Financial Officer (Age 68)
  • Dr. Randolph C. Steer, Consultant (Age 69)
  • Dr. William M. Wardell M.D., Ph.D., Head of Clinical & Regulatory Review Board (Age 80)
  • Ms. Karen Struck, Investor Relations Professional

How do I buy shares of Capstone Therapeutics?

Shares of CAPS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Capstone Therapeutics' stock price today?

One share of CAPS stock can currently be purchased for approximately $0.0260.

How big of a company is Capstone Therapeutics?

Capstone Therapeutics has a market capitalization of $1.41 million and generates $2 million in revenue each year.

What is Capstone Therapeutics' official website?

The official website for Capstone Therapeutics is http://www.capstonethx.com/.

How can I contact Capstone Therapeutics?

Capstone Therapeutics' mailing address is 1275 W. Washington Street Suite 104, Tempe AZ, 85281. The biotechnology company can be reached via phone at 602-286-5520 or via email at [email protected]

MarketBeat Community Rating for Capstone Therapeutics (OTCMKTS CAPS)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  46 (Vote Outperform)
Underperform Votes:  27 (Vote Underperform)
Total Votes:  73
MarketBeat's community ratings are surveys of what our community members think about Capstone Therapeutics and other stocks. Vote "Outperform" if you believe CAPS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CAPS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel